NeoGenomics Reports Record Revenue of $76 Million with 17% Organic Revenue Growth in the Fourth Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
NeoGenomics (NEO) Tops Q4 EPS by 1c, Revenues Beat; Offers FY19 Revenue Guidance
February 19, 2019 7:09 AM ESTNeoGenomics (NASDAQ: NEO) reported Q4 EPS of $0.06, $0.01 better than the analyst estimate of $0.05. Revenue for the quarter came in at $76.5 million versus the consensus estimate of $71.43 million.
Consolidated revenue increased 24.5% to $76.5 millionConsolidated revenue increased 17.0% to $71.8 million, excluding GenoptixClinical Services revenue increased 23.3% to $65.9 millionPharma Services revenue increased 32.6% to $10.6 millionGross profit increased 38.7% to $37.1 millionGross margin increased approximately 500 basis... More